摘要
目的:比较ST段抬高型心肌梗死(STEMI)患者尿激酶静脉溶栓后分别应用比伐芦定和替罗非班治疗的临床效果,以及对其血小板最大聚集率和预后的影响。方法:选取2018年6月—2020年7月在本院接受治疗的STEMI患者102例,采用随机数表法分为观察组(53例)和对照组(49例)。观察组患者尿激酶静脉溶栓后采用比伐芦定治疗,对照组采用替罗非班治疗,比较两组治疗前后血小板最大聚集率、凝血活酶时间(APTT)以及不良事件发生情况。结果:治疗后,两组血小板最大聚集率均降低(P<0.05),且观察组低于对照组(P<0.05);两组APTT均上升(P<0.05),且观察组高于对照组(P<0.05);观察组不良事件总发生率低于对照组(P<0.05)。结论:与替罗非班比较,比伐芦定降低STEMI患者尿激酶静脉溶栓后血小板最大聚集率、提高APTT效果更显著,预后情况更佳。
Objective:To explore the curative effect of bivalirudin and tirofiban on patients with ST-segment elevation myocardial infarction(STEMI)after urokinase intravenous thrombolysis,as well as the effects on maximum platelet aggregation rate(MPAR)and prognosis.Methods:A total of 102 STEMI patients who were treated in the hospital from June 2018 to July 2020 were enrolled and divided into observation group(53 cases)and control group(49 cases)by random number table method.After urokinase intravenous thrombolysis,observation group was treated with bivalirudin,while control group was treated with tirofiban.MPAR,activated partial thromboplastin time(APTT)and the occurrence of adverse events before and after treatment were observed and compared between the two groups.Results:After treatment,MPAR in both groups was decreased(P<0.05),which was lower in observation group than control group(P<0.05).After treatment,APTT in both groups was increased(P<0.05),which was higher in observation group than control group(P<0.05).The total incidence of adverse events in observation group was lower than that in control group(P<0.05).Conclusion:Compared with tirofiban,bivalirudin can significantly reduce MPAR in STEMI patients after urokinase intravenous thrombolysis,and increase APTT,with better prognosis.
作者
李恒
LI Heng(Yichuan County People's Hospital,Yichuan Henan 471000,China)
出处
《药品评价》
CAS
2020年第22期23-24,27,共3页
Drug Evaluation
关键词
ST段抬高型心肌梗死
尿激酶静脉溶栓
血小板最大聚集率
凝血活酶时间
预后
ST-segment Elevation Myocardial Infarction
Urokinase Intravenous Thrombolysis
Maximum Platelet Aggregation Rate
Activated Partial Thromboplastin Time
Prognosis
